Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)

Conditions

Alzheimer's Disease

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.


  • Trial with
    Alzheimer's Therapeutic Research Institute
  • Start Date
    03/27/2017
  • End Date
    10/30/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image
  • Last Updated
    02/22/2018
  • Study HIC
    #1608018296